<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29636047</article-id><article-id pub-id-type="pmc">5891985</article-id><article-id pub-id-type="publisher-id">701</article-id><article-id pub-id-type="doi">10.1186/s12933-018-0701-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9874-3766</contrib-id><name><surname>Chen</surname><given-names>Xiao-min</given-names></name><address><email>chenxiaomin0517@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wen-qiang</given-names></name><address><email>nfmzwq@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Yuan</given-names></name><address><email>411954353@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Li-fen</given-names></name><address><email>670298752@qq.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chan-chan</given-names></name><address><email>2513429464@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Chuan-mei</given-names></name><address><email>2476921372@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0604 9729</institution-id><institution-id institution-id-type="GRID">grid.413280.c</institution-id><institution>Department of Endocrinology and Metabolism, </institution><institution>Zhongshan Hospital Xiamen University, </institution></institution-wrap>201-209 Hubin South Road, Xiamen, 361004 People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label>Guangzhou Medicine University Second Affiliated Hospital, 250-296 Changgang East Road, Guangzhou, 510260 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>17</volume><elocation-id>53</elocation-id><history><date date-type="received"><day>5</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>5</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">It has been suggested that liraglutide could have an impact on glucose and lipid metabolism disorder and adhesion molecule activation, which may play important roles in the vascular damage of diabetes. In this study, we examined the effects of liraglutide versus metformin on non-esterified free fatty acids, beta-cell insulin secretion, and adhesion molecule levels in patients with recent-onset type 2 diabetes mellitus.</p></sec><sec><title>Methods</title><p id="Par2">In this study, 60 patients newly diagnosed with type 2 diabetes mellitus (mean age 33.97&#x02009;&#x000b1;&#x02009;5.67&#x000a0;years) were randomly assigned to receive once-daily subcutaneous liraglutide or oral metformin. Before the study and after the 8-week treatment period, a 75&#x000a0;g oral glucose tolerance test was performed. Plasma glucose, lipids and lipoprotein, plasma insulin, glycaemic and insulin responses, non-esterified free fatty acids (NEFA), and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were evaluated.</p></sec><sec><title>Results</title><p id="Par3">After 8&#x000a0;weeks, 120&#x000a0;min of NEFA (155&#x02009;&#x000b1;&#x02009;125 vs 99&#x02009;&#x000b1;&#x02009;73&#x000a0;&#x000b5;mol/L, <italic>P&#x02009;</italic>=&#x02009;0.026) and the levels of sVCAM-1 (465&#x02009;&#x000b1;&#x02009;136 vs 382&#x02009;&#x000b1;&#x02009;131&#x000a0;ng/ml, <italic>P&#x02009;</italic>=&#x02009;0.013) significantly decreased, while the early phase insulin secretion index (24.94 [7.78, 38.89] vs. 31.13 [17.67, 59.09], <italic>P&#x02009;</italic>=&#x02009;0.031), fasting plasma insulin (104 [51, 123] vs 113 [54, 171]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.015), 60&#x000a0;min plasma insulin (326 [165, 441] vs 471 [334, 717]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.005), 120&#x000a0;min plasma insulin (401 [193, 560] vs 500 [367, 960]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.047), and insulin area under the curve (AUCins) (648 [321, 742] vs 738 [451, 1118]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.005) remarkably increased for patients in the liraglutide treatment group. The levels of sVCAM-1 dramatically decreased after 8&#x000a0;weeks of liraglutide treatment (503&#x02009;&#x000b1;&#x02009;182 vs 382&#x02009;&#x000b1;&#x02009;131&#x000a0;ng/ml, <italic>P&#x02009;</italic>=&#x02009;0.046) compared to that of the metformin treatment group. At the same time, the differences before and after liraglutide treatment in 120&#x000a0;min of NEFA (&#x02212;&#x02009;32 [&#x02212;&#x02009;96, &#x02212;&#x02009;5] vs 5 [&#x02212;&#x02009;35, 38]&#x000a0;&#x000b5;mol/L, <italic>P&#x02009;</italic>=&#x02009;0.033) and AUCins (738 [451, 1118] vs 594 [357, 1216]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.014) were remarkably enhanced compared to that of the metformin therapy. Nevertheless, there were no significant differences in fasting NEFA after liraglutide or metformin treatment. The reduction of 120&#x000a0;min NEFA (&#x00394;NEFA) was positively correlated with the decrease of sVCAM-1 (&#x00394;sVCAM-1) after 8&#x000a0;weeks of liraglutide treatment (<italic>r&#x02009;</italic>=&#x02009;0.523, <italic>P&#x02009;</italic>=&#x02009;0.003).</p></sec><sec><title>Conclusions</title><p id="Par4">Our results demonstrate that liraglutide administration is more effective than metformin in reducing 120&#x000a0;min NEFA and suppressing sVCAM-1 levels for recent-onset type 2 diabetes mellitus. We suggest that this outcome may be because liraglutide is associated with potentiating insulin secretion capacity, inhibiting vascular inflammatory cytokines, and antagonizing atherosclerosis.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12933-018-0701-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Liraglutide</kwd><kwd>Metformin</kwd><kwd>NEFA</kwd><kwd>sVCAM-1</kwd><kwd>Type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source><institution>Science and Technology Benefit Fund of Xiamen Technology Bureau</institution></funding-source><award-id>3502Z20154027</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Xiao-min</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par41">It has been well documented that atherosclerosis is the major cause of death in type 2 diabetic patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Dyslipidaemia plays an important role in the pathogenesis of atherosclerosis and even to insulin resistance [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Dyslipidaemia is associated with increased lipolysis and the release of higher amounts non-esterified fatty acids (NEFAs) into the bloodstream [<xref ref-type="bibr" rid="CR5">5</xref>]. Hyperglycaemia promotes lipolysis and leads to chronic exposure to NEFA [<xref ref-type="bibr" rid="CR6">6</xref>]. Several studies have shown that the elevated serum level of NEFA contributes to vascular damage in diabetes [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par42">Plasma NEFAs promote a systemic insulin resistance state and are correlated with inflammation in atheromatous plaques [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The levels of NEFAs seem to be modified by dietary or therapeutic intervention. Glucagon-like peptide-1 (GLP-1) has recently received attention as a novel drug in the antidiabetic field [<xref ref-type="bibr" rid="CR9">9</xref>]. The long-acting GLP-1 analogue liraglutide (LRG) exhibits pleiotropic effects on glucolipid metabolism, &#x003b2;-cell insulin secretion and anti-atherosclerosis [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Nevertheless, the precise mechanism by which liraglutide modulates lipids metabolism remains unclear.</p><p id="Par43">Therefore, the aim of this study is to evaluate whether liraglutide could be more effective at suppressing lipolysis, ameliorating glucose and lipid metabolism, enhancing beta-cell functions, and inhibiting vascular inflammatory markers compared to metformin in recent-onset type 2 diabetes mellitus.</p></sec><sec id="Sec2"><title>Subjects and methods</title><sec id="Sec3"><title>Ethical approval</title><p id="Par44">Ethical approval was granted by the Institutional Review Board of Xiamen University Affiliated Zhongshan Hospital according to Helsinki Declaration II. Written informed consent was signed by and obtained from each participant.</p></sec><sec id="Sec4"><title>Participants</title><p id="Par45">Participants were recruited between October 2015 and December 2016 at Zhongshan Hospital Xiamen University in P. R. China. The inclusion criteria were set to select participants: the patients had an initial diagnosis of type 2 diabetes mellitus who met the World Health Organization criteria for type 2 diabetes and were aged 18&#x02013;40&#x000a0;years, with a body mass index (BMI) of 25&#x02013;35&#x000a0;kg/m<sup>2</sup>, HbA1c of 6.5&#x02013;9%, and fasting serum triglycerides of 0.5&#x02013;5&#x000a0;mmol/L. Main exclusion criteria included the following: type 1 diabetes, recent acute complications including diabetic ketoacidosis and hyperglycaemic hyperosmolar state, impaired liver function, impaired renal function (creatinine clearance&#x02009;&#x0003c;&#x02009;60&#x000a0;ml/min) [<xref ref-type="bibr" rid="CR16">16</xref>], pregnancy and breast bleeding, and other factors that affect glucose and lipid changes.</p></sec><sec id="Sec5"><title>Study design and procedures</title><p id="Par46">This study is a randomized, parallel, active comparator trial in 60 participants. The treatment order of liraglutide or metformin was determined through random assignment (1:1). All individuals who received liraglutide treatment started injection doses at 0.6&#x000a0;mg/day. After 1&#x000a0;week of injection, the dose was increased to 1.2&#x000a0;mg/day. Participants in another group who received metformin received an oral dose in the range of 1&#x02013;2&#x000a0;g/day. After an overnight fast, a 75&#x000a0;g oral glucose tolerance test (OGTT) was conducted for each participant. Blood samples were drawn before and 30, 60, 120&#x000a0;min after OGTT, respectively. Participants in the liraglutide treatment group were instructed to administer the Flexpen device. Participants were also informed of medication precautions before metformin treatment. All participants received lifestyle intervention health education from professional nurse. The total planned treatment period was 8&#x000a0;weeks. There were a total of 3 follow-up visits, once per month. The plasma glucose, blood pressure, body weight, waist circumference and hip circumference were measured, and adverse events were monitored by investigators. At the end of the trial, the clinical and laboratory indices were assessed, as previously described.</p></sec><sec id="Sec6"><title>Clinical measurement and laboratory test</title><p id="Par47">Weight, waist circumference (WC), and hip circumference were measured by professional nurses. Participants removed clothing and shoes prior to measurements. WC was measured midway between the lowest rib and the top of the iliac crest. Hip circumference was measured around the peak of the buttocks. Body mass index (BMI) was calculated as the body weight (BW) in kilograms divided by the square of the patient&#x02019;s height in metres. Measurements of systolic blood pressure and diastolic blood pressure (SBP and DBP) were performed 2 times with a mercury manometer on the right arm after 5&#x000a0;min in the sitting position. The mean values of measurements were recorded.</p><p id="Par48">Participants were instructed to refrain from excessive physical exercise and to eat normally 3&#x000a0;days before the test, with no less than 200 grams of carbohydrates daily. After fasting overnight (8&#x02013;10&#x000a0;h), a 2-h OGTT test was performed on each subject. Fasting plasma glucose (FPG), 30&#x000a0;min PG, 60&#x000a0;min PG, and 120&#x000a0;min PG were measured by the hexokinase method. Subjects&#x02019; renal and liver functions, plasma lipids and lipoprotein concentrations including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were assayed using standard methods (Roche cobas8000 automatic biochemical analyser). HbA1c was analysed by HPLC (Bio-Rad, Inc., Hercules, CA, USA). Plasma insulin levels were measured using the electrochemiluminescence immunoassay (ECLI). NEFA levels were measured in the Xiamen Diabetes Hospital using Abbott c16000 automatic biochemical analyser. Soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) were measured in the plasma of patients using quantikine ELISA kits (R&#x00026;D systems, Inc., Minneapolis, USA). Plasminogen activator inhibitor 1 (PAI-1) concentrations were assessed using ELISA assays (Multi sciences, Inc., Hangzhou, PRC). The intra-assay and inter-assay coefficients of variation (CV) of the ELISA kits mentioned above were all less than 10%. The early phase insulin secretion index was calculated as (&#x00394;I30/&#x00394;G30)&#x02009;=&#x02009;([insulin at 30&#x000a0;min]&#x02009;&#x02212;&#x02009;[insulin at 0&#x000a0;min])/([glucose at 30&#x000a0;min]&#x02009;&#x02212;&#x02009;[glucose at 0&#x000a0;min]) [<xref ref-type="bibr" rid="CR17">17</xref>]. The area under the curve (AUC) for plasma insulin during the OGTT was calculated using the trapezoidal rule [<xref ref-type="bibr" rid="CR18">18</xref>]. Deltas (&#x00394;) are presented as the difference before and after treatment, which were available for the variables &#x00394;NEFA, &#x00394;sVCAM-1, &#x00394;AUCins, and &#x00394;I30/&#x00394;G30. Deltas were also considered to express the difference between 120&#x000a0;min values and fasting values in &#x00394;TC and &#x00394;LDL-C.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par49">SPSS version 21 (SPSS software, IBM Inc., USA) and GraphPad Prism version 5.0 (GraphPad software, Inc., La Jolla, CA, USA) were utilized for statistical analysis and the construction of graphs. The normal distribution data are presented as the mean&#x02009;&#x000b1;&#x02009;standard deviation. Comparisons of basic characteristics between groups were made using an unpaired <italic>t</italic> test. Comparisons of baseline and post-treatment data in the same group were made using a paired <italic>t</italic> test. The skewed distribution variables are expressed as the median (interquartile rang), and the Mann&#x02013;Whitney <italic>U</italic> test or Wilcoxon signed rank test was performed. The Mann&#x02013;Whitney <italic>U</italic> test was used to determine the differences from baseline with a final measurement at 8&#x000a0;weeks for 120&#x000a0;min NEFA, insulin secretion capacity including fasting insulin, 30&#x000a0;min insulin, 60&#x000a0;min insulin, 120&#x000a0;min insulin, &#x00394;I30/&#x00394;G30, and AUCins between the liraglutide and metformin group. At the same time, the Mann&#x02013;Whitney <italic>U</italic> test was carried out to determine the differences between 120&#x000a0;min values and fasting values on TC and LDL-C in the metformin group. Spearman rank correlations were performed to determine the relationship of &#x00394;NEFA with &#x00394;sVCAM-1, &#x00394;AUCins and &#x00394;I30/&#x00394;G30 after 8&#x000a0;weeks of treatment. The Chi squared (<italic>&#x003c7;</italic><sup><italic>2</italic></sup>) test was used for categorical variables. Two-tailed significance was set at <italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Comparisons of clinical and laboratory characteristics of the study participants</title><p id="Par50">The patient characteristics grouped by either liraglutide or metformin treatment are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. In the baseline analysis, the differences in participants&#x02019; age, BW, BMI, SBP, DBP, WC and hip circumference between the two groups were not statistically significant. HbA1c, FPG, 60&#x000a0;min PG, 120&#x000a0;min PG, NEFA, lipids and lipoprotein concentrations (including TC, TG, LDL-C, HDL-C), insulin secretion capacity, sVCAM-1, sICAM-1, and PAI-1 were similar between the two groups, but 30&#x000a0;min PG was higher at baseline in the liraglutide treatment group.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Liraglutide (n&#x02009;=&#x02009;30)</th><th align="left">Metformin (n&#x02009;=&#x02009;30)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">32.67&#x02009;&#x000b1;&#x02009;5.46</td><td align="left">35.27&#x02009;&#x000b1;&#x02009;5.85</td><td char="." align="char">0.219</td></tr><tr><td align="left">Male/female (n)</td><td align="left">20/10</td><td align="left">20/10</td><td char="." align="char">1.000</td></tr><tr><td align="left">BW (kg)</td><td align="left">81&#x02009;&#x000b1;&#x02009;17</td><td align="left">72&#x02009;&#x000b1;&#x02009;11</td><td char="." align="char">0.104</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">28.63&#x02009;&#x000b1;&#x02009;3.86</td><td align="left">26.16&#x02009;&#x000b1;&#x02009;3.1</td><td char="." align="char">0.063</td></tr><tr><td align="left">Waist circumference (cm)</td><td align="left">92.20&#x02009;&#x000b1;&#x02009;11.99</td><td align="left">88.27&#x02009;&#x000b1;&#x02009;8.22</td><td char="." align="char">0.304</td></tr><tr><td align="left">Hip circumference (cm)</td><td align="left">99.87&#x02009;&#x000b1;&#x02009;6.02</td><td align="left">96.33&#x02009;&#x000b1;&#x02009;5.77</td><td char="." align="char">0.112</td></tr><tr><td align="left">SBP (mmHg)</td><td align="left">122&#x02009;&#x000b1;&#x02009;16</td><td align="left">120&#x02009;&#x000b1;&#x02009;11</td><td char="." align="char">0.643</td></tr><tr><td align="left">DBP (mmHg)</td><td align="left">79&#x02009;&#x000b1;&#x02009;12</td><td align="left">81&#x02009;&#x000b1;&#x02009;7</td><td char="." align="char">0.719</td></tr><tr><td align="left" colspan="4">Cholesterol (mmol/L)</td></tr><tr><td align="left">&#x000a0;Fasting value</td><td align="left">4.79&#x02009;&#x000b1;&#x02009;0.87</td><td align="left">5.02&#x02009;&#x000b1;&#x02009;0.79</td><td char="." align="char">0.444</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min value</td><td align="left">4.45&#x02009;&#x000b1;&#x02009;1.02</td><td align="left">4.55&#x02009;&#x000b1;&#x02009;0.81</td><td char="." align="char">0.777</td></tr><tr><td align="left" colspan="4">Triglycerides (mmol/L)</td></tr><tr><td align="left">&#x000a0;Fasting value</td><td align="left">1.82&#x02009;&#x000b1;&#x02009;0.74</td><td align="left">1.99&#x02009;&#x000b1;&#x02009;0.74</td><td char="." align="char">0.539</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min value</td><td align="left">2.07&#x02009;&#x000b1;&#x02009;1.23</td><td align="left">1.97&#x02009;&#x000b1;&#x02009;0.68</td><td char="." align="char">0.802</td></tr><tr><td align="left" colspan="4">LDL-C (mmol/L)</td></tr><tr><td align="left">&#x000a0;Fasting value</td><td align="left">3.61&#x02009;&#x000b1;&#x02009;0.82</td><td align="left">3.78&#x02009;&#x000b1;&#x02009;0.68</td><td char="." align="char">0.535</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min value</td><td align="left">3.16&#x02009;&#x000b1;&#x02009;0.70</td><td align="left">3.28&#x02009;&#x000b1;&#x02009;0.70</td><td char="." align="char">0.639</td></tr><tr><td align="left" colspan="4">HDL-C (mmol/L)</td></tr><tr><td align="left">&#x000a0;Fasting value</td><td align="left">1.12&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">1.20&#x02009;&#x000b1;&#x02009;0.26</td><td char="." align="char">0.448</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min value</td><td align="left">1.04&#x02009;&#x000b1;&#x02009;0.35</td><td align="left">1.07&#x02009;&#x000b1;&#x02009;0.23</td><td char="." align="char">0.793</td></tr><tr><td align="left">&#x000a0;HbA<sub>1</sub>c (%)</td><td align="left">8.49&#x02009;&#x000b1;&#x02009;1.81</td><td align="left">7.77&#x02009;&#x000b1;&#x02009;1.44</td><td char="." align="char">0.238</td></tr><tr><td align="left">&#x000a0;FPG (mmol/L)</td><td align="left">9.40&#x02009;&#x000b1;&#x02009;2.32</td><td align="left">8.45&#x02009;&#x000b1;&#x02009;1.57</td><td char="." align="char">0.198</td></tr><tr><td align="left">&#x000a0;30&#x000a0;min PG (mmol/L)</td><td align="left">15.43&#x02009;&#x000b1;&#x02009;2.96</td><td align="left">13.03&#x02009;&#x000b1;&#x02009;2.72</td><td char="." align="char">0.028</td></tr><tr><td align="left">&#x000a0;60&#x000a0;min PG (mmol/L)</td><td align="left">18.19&#x02009;&#x000b1;&#x02009;3.60</td><td align="left">16.43&#x02009;&#x000b1;&#x02009;4.13</td><td char="." align="char">0.224</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min PG (mmol/L)</td><td align="left">17.68&#x02009;&#x000b1;&#x02009;4.38</td><td align="left">14.47&#x02009;&#x000b1;&#x02009;5.05</td><td char="." align="char">0.074</td></tr><tr><td align="left">&#x000a0;Fasting insulin (mIU/L)</td><td align="left">104 (51, 123)</td><td align="left">76 (60, 150)</td><td char="." align="char">0.724</td></tr><tr><td align="left">&#x000a0;30&#x000a0;min insulin (mIU/L)</td><td align="left">271 (136, 298)</td><td align="left">211 (118, 444)</td><td char="." align="char">0.917</td></tr><tr><td align="left">&#x000a0;60&#x000a0;min insulin (mIU/L)</td><td align="left">326 (165, 441)</td><td align="left">368 (242, 731)</td><td char="." align="char">0.152</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min insulin (mIU/L)</td><td align="left">401 (193, 560)</td><td align="left">475 (286, 1060)</td><td char="." align="char">0.178</td></tr><tr><td align="left">&#x000a0;AUCins (mIU/L)</td><td align="left">648 (321, 742)</td><td align="left">615 (381, 1167)</td><td char="." align="char">0.520</td></tr><tr><td align="left">&#x000a0;&#x00394;I30/&#x00394;G30</td><td align="left">24.94 (7.78, 38.89)</td><td align="left">30.18 (10.4, 53.75)</td><td char="." align="char">0.272</td></tr><tr><td align="left" colspan="4">NEFA (&#x003bc;mol/L)</td></tr><tr><td align="left">&#x000a0;Fasting value</td><td align="left">620&#x02009;&#x000b1;&#x02009;468</td><td align="left">485&#x02009;&#x000b1;&#x02009;225</td><td char="." align="char">0.325</td></tr><tr><td align="left">&#x000a0;120&#x000a0;min value</td><td align="left">155&#x02009;&#x000b1;&#x02009;125</td><td align="left">101&#x02009;&#x000b1;&#x02009;53</td><td char="." align="char">0.309</td></tr><tr><td align="left">&#x000a0;sVCAM-1 (ng/ml)</td><td align="left">465&#x02009;&#x000b1;&#x02009;136</td><td align="left">485&#x02009;&#x000b1;&#x02009;122</td><td char="." align="char">0.669</td></tr><tr><td align="left">&#x000a0;sICAM-1 (ng/ml)</td><td align="left">113&#x02009;&#x000b1;&#x02009;40</td><td align="left">168&#x02009;&#x000b1;&#x02009;110</td><td char="." align="char">0.085</td></tr><tr><td align="left">&#x000a0;PAI-1 (ng/ml)</td><td align="left">69.52 &#x02009;&#x000b1;&#x02009;45.75</td><td align="left">51.34 &#x02009;&#x000b1;&#x02009;38.87</td><td char="." align="char">0.227</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation or median (interquartile rang)</p><p><italic>BW</italic> body weight, <italic>BMI</italic> body mass index, <italic>SBP</italic> systolic blood pressure, <italic>DBP</italic> diatolic blood pressure, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>HDL-C</italic> high-density lipoprotein cholesterol, <italic>HbA</italic><sub><italic>1</italic></sub><italic>c</italic> glycated haemoglobin, <italic>FPG</italic> fasting plasma glucose, <italic>AUCins</italic> insulin area under the curve, <italic>NEFA</italic> non-esterified fatty acids, <italic>sVCAM-1</italic> soluble vascular cell adhesion molecule-1, <italic>sICAM-1</italic> soluble intercellular adhesion molecule-1, <italic>PAI-1</italic> plasminogen activator inhibitors-1</p></table-wrap-foot></table-wrap>
</p><p id="Par51">After 8-week metformin treatment, fasting total cholesterol (TC) and low density lipoprotein cholesterin (LDL-C) were remarkably lower compared to baseline (5.02&#x02009;&#x000b1;&#x02009;0.79 vs 4.45&#x02009;&#x000b1;&#x02009;0.28&#x000a0;mmol/L, <italic>P&#x02009;</italic>=&#x02009;0.006), (3.78&#x02009;&#x000b1;&#x02009;0.68 vs 3.18&#x02009;&#x000b1;&#x02009;0.88&#x000a0;mmol/L, <italic>P&#x02009;</italic>=&#x02009;0.012). At the same time, metformin therapy also reduced 120&#x000a0;min TC (4.55&#x02009;&#x000b1;&#x02009;0.81 vs 4.10&#x02009;&#x000b1;&#x02009;1.21&#x000a0;mmol/L, <italic>P&#x02009;</italic>=&#x02009;0.036) and 120&#x000a0;min LDL-C (3.28&#x02009;&#x000b1;&#x02009;0.7 vs 2.76&#x02009;&#x000b1;&#x02009;0.91&#x000a0;mmol/L, <italic>P&#x02009;</italic>=&#x02009;0.008) after OGTT. However, in the present study, there were no significant differences between 120&#x000a0;min values and fasting values in &#x00394;TC and &#x00394;LDL-C with respect to metformin treatment. Furthermore, no significant differences were found in plasma lipids and lipoprotein after liraglutide treatment compared with the basal values (shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p><p id="Par52">We found a significant reduction in waist circumference (92&#x02009;&#x000b1;&#x02009;12 vs 88&#x02009;&#x000b1;&#x02009;11&#x000a0;cm, <italic>P&#x02009;</italic>=&#x02009;0.001) and body weight (81&#x02009;&#x000b1;&#x02009;17 vs 78&#x02009;&#x000b1;&#x02009;16&#x000a0;kg, <italic>P&#x02009;</italic>=&#x02009;0.001), as well as BMI (28.63&#x02009;&#x000b1;&#x02009;3.86 vs 27.67&#x02009;&#x000b1;&#x02009;3.62&#x000a0;kg/m<sup>2</sup>, <italic>P&#x02009;</italic>=&#x02009;0.001), with liraglutide treatment. Metformin treatment also showed a slight downtrend in BW and BMI, although the difference was not significant (shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p></sec><sec id="Sec10"><title>Liraglutide treatment elevated insulin secretion capacity and decreased plasma glucose</title><p id="Par53">Early phase insulin secretion index (&#x00394;I30/&#x00394;G30) (24.94 [7.78, 38.89] vs 31.13 [17.67, 59.09], P&#x02009;=&#x02009;0.031), fast plasma insulin (104 [51, 123] vs 113 [54, 171] mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.015), 60&#x000a0;min plasma insulin (326 [165, 441] vs 471 [334, 717]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.005), 120&#x000a0;min plasma insulin (401 [193, 560] vs 500 [367, 960]&#x000a0;mIU/L, <italic>P&#x02009;</italic>=&#x02009;0.047), and insulin area under the curve (AUCins) (648 [321, 742] vs 738 [451, 1118]&#x000a0;mIU/L, P&#x02009;=&#x02009;0.005) significantly increased with liraglutide treatment. The differences in AUCins (&#x00394;AUCins) before and after liraglutide treatment (738 [451, 1118] vs 594 [357, 1216]&#x000a0;mIU/L, P&#x02009;=&#x02009;0.014) were remarkably enhanced compared to that in metformin therapy, but differences in &#x00394;I30/&#x00394;G30 before and after liraglutide treatment (6.01 [1.79, 28.46] vs &#x02212;&#x02009;2.62 [&#x02212;&#x02009;14.85, 8.76], P&#x02009;=&#x02009;0.065) were not significant between the two groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In fact, both liraglutide (8.49&#x02009;&#x000b1;&#x02009;1.81 vs 6.92&#x02009;&#x000b1;&#x02009;0.81%, <italic>P&#x02009;</italic>=&#x02009;0.002) and metformin treatment (7.77&#x02009;&#x000b1;&#x02009;1.44 vs 6.43&#x02009;&#x000b1;&#x02009;0.71%, <italic>P&#x02009;</italic>=&#x02009;0.001) could reduce HbA1c values. FPG, 30&#x000a0;min PG, 60&#x000a0;min PG and 120 min PG all decreased after liraglutide treatment, but only FPG was significantly reduced after metformin treatment (shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Comparisons of sVCAM-1, 120&#x000a0;min NEFA, AUCins and &#x00394;I30/&#x00394;G30 levels after 8-week treatment between liraglutide and metformin group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Liraglutide</th><th align="left">Metformin</th><th align="left">Difference</th><th align="left">P-value</th></tr></thead><tbody><tr><td align="left">sVCAM-1 (ng/ml)</td><td align="left">382&#x02009;&#x000b1;&#x02009;131</td><td align="left">503&#x02009;&#x000b1;&#x02009;182</td><td align="left"/><td char="." align="char">0.046</td></tr><tr><td align="left">120&#x000a0;min NEFA (&#x003bc;mol/L)<sup>a</sup></td><td align="left">&#x02212;&#x02009;32 (&#x02212;&#x02009;96, &#x02212;&#x02009;5)</td><td align="left">5 (&#x02212;&#x02009;35, 38)</td><td align="left">&#x02212;&#x02009;20.5 (&#x02212;&#x02009;46.5, 31.5)</td><td char="." align="char">0.033</td></tr><tr><td align="left">AUCins (mIU/L)<sup>a</sup></td><td align="left">738 (451, 1118)</td><td align="left">594 (357, 1216)</td><td align="left">39 (&#x02212;&#x02009;33, 227)</td><td char="." align="char">0.014</td></tr><tr><td align="left">&#x00394;I30/&#x00394;G30<sup>a</sup></td><td align="left">6.01 (1.79, 28.46)</td><td align="left">&#x02212;&#x02009;2.62 (&#x02212;&#x02009;14.85,8.76)</td><td align="left">4.56 (&#x02212;&#x02009;4.82, 12.99)</td><td char="." align="char">0.065</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation or median (interquartile rang)</p><p><italic>sVCAM-1</italic> soluble vascular cell adhesion molecule-1, <italic>NEFA</italic> non-esterified fatty acids, <italic>AUCins</italic> insulin area under the curve</p><p>&#x00394;I30/&#x00394;G30&#x02009;=&#x02009;[(insulin at 30&#x000a0;min)&#x02009;&#x02212;&#x02009;(insulin at 0&#x000a0;min)]/[(glucose at 30&#x000a0;min)&#x02009;&#x02212;&#x02009;(glucose at 0&#x000a0;min)]</p><p><sup>a</sup>Difference between pre-treatment and post-treatment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Liraglutide treatment inhibited 120 min non-esterified free fatty acids</title><p id="Par54">After 8&#x000a0;weeks, there was a progressive decrease in the levels of 120&#x000a0;min NEFA (155&#x02009;&#x000b1;&#x02009;125 vs 99&#x02009;&#x000b1;&#x02009;73&#x000a0;&#x000b5;mol/L, <italic>P&#x02009;</italic>=&#x02009;0.026) after liraglutide treatment. Compared with metformin therapy, the reduction in 120&#x000a0;min NEFA (&#x00394;NEFA) remarkably increased after 8-week liraglutide treatment [&#x02212;&#x02009;32 (&#x02212;&#x02009;96, &#x02212;&#x02009;5) vs 5 (&#x02212;&#x02009;35, 38) &#x000b5;mol/L, P&#x02009;=&#x02009;0.033] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The changes in 120&#x000a0;min NEFA showed a slight increase after metformin therapy (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). There were no significant changes in fasting non-esterified free fatty acids after liraglutide and metformin treatment.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p><bold>a</bold> 120&#x000a0;min non-esterified fatty acid (NEFA) before and after 8-week treatment with liraglutide and metformin. <bold>b</bold> The difference of NEFA (&#x02206; NEFA) between baseline and after 8-week treatment with liraglutide and metformin *<italic>P&#x02009;</italic>&#x0003c;0.05 vs the metformin group</p></caption><graphic xlink:href="12933_2018_701_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec12"><title>Liraglutide treatment inhibited vascular inflammatory marker levels</title><p id="Par55">We found a significant reduction in sVCAM-1 (465&#x02009;&#x000b1;&#x02009;136 vs 382&#x02009;&#x000b1;&#x02009;131&#x000a0;ng/ml, <italic>P&#x02009;</italic>=&#x02009;0.013) after liraglutide treatment compared with baseline. Compared to metformin therapy, the levels of sVCAM-1 were remarkably suppressed after 8-week liraglutide treatment (382&#x02009;&#x000b1;&#x02009;131 vs 503&#x02009;&#x000b1;&#x02009;182&#x000a0;ng/ml, <italic>P&#x02009;</italic>=&#x02009;0.046) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). However, there were no significant differences in sICAM-1 and PAI-1 levels before and after liraglutide and metformin therapy (shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). In all subjects combined, the reduction of 120&#x000a0;min NEFA (&#x00394;NEFA) was positively correlated with the decrease of sVCAM-1 (&#x00394;sVCAM-1) after 8-week liraglutide treatment (<italic>r&#x02009;</italic>=&#x02009;0.523, <italic>P&#x02009;</italic>=&#x02009;0.003), which was not significantly negatively correlated with the increase of AUCins (&#x00394;AUCins) (<italic>r&#x02009;</italic>=&#x02009;&#x02212;&#x02009;0.286, <italic>P&#x02009;</italic>=&#x02009;0.125) and &#x00394;I30/&#x00394;G30 (<italic>r&#x02009;</italic>=&#x02009;&#x02212;&#x02009;0.150, <italic>P&#x02009;</italic>=&#x02009;0.429) (shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Changes of soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after 8-week treatment with liraglutide and metformin</p></caption><graphic xlink:href="12933_2018_701_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par56">Our results indicate that prolonged liraglutide treatment for 8&#x000a0;weeks effectively inhibited 120&#x000a0;min non-esterified free fatty acids (NEFAs). We utilized a 75&#x000a0;g oral glucose tolerance test (OGTT) to evaluate the changes of NEFA, which should avoid the effects of a high-fat diet on postprandial lipid metabolism. As observed in this study, NEFA levels gradually decreased after glucose uptake, and 120&#x000a0;min NEFAs are dramatically lower than fasting NEFAs. Furthermore, our data show that liraglutide exhibits greater stimulation on the insulin secretion capacity, including early phase insulin secretion, fast plasma insulin, 60&#x000a0;min plasma insulin, 120&#x000a0;min plasma insulin and insulin area under the curve (AUCins) relative to those at baseline. Previous research has shown that insulin could suppress chylomicron synthesis from human jejunal explants [<xref ref-type="bibr" rid="CR19">19</xref>]. Additionally, circulating FFAs derived from chylomicron are reduced in the hyperinsulinaemia state, as insulin prevents lipolysis in the regulation of hepatic and intestinal lipoprotein production [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par57">Our data demonstrated that after the 8-week treatment period, the reduction in 120&#x000a0;min NEFA (&#x00394;NEFA) was greater increased, and the increase in AUCins (&#x00394;AUCins) was also enhanced in liraglutide treatment relative to metformin treatment. Consequently, in this study, liraglutide therapy exhibited beneficial effects in ameliorating the &#x003b2;-cell secretion capacity and suppressing free fatty acid production. However, the precise mechanisms by which glucagon-like peptide-1 affects lipids metabolism are less certain. It has been hypothesized that enterocyte GLP-1 receptor signalling is essential for postprandial lipoprotein synthesis and secretion, reduces intestinal lipid production and absorption, and prevents the postprandial increases in triacylglycerol, cholesterol and apo-B48 levels [<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, GLP-1 is related to the direct modulation of fatty acid binding protein 2 (FABP2), which is required for the formation of apo-B48 containing chylomicrons [<xref ref-type="bibr" rid="CR23">23</xref>]. In addition, even through enhanced insulin secretion, GLP-1 induced prolonged reductions in NEFA concentrations after meals, suppressed postprandial rises in ApoCIII [<xref ref-type="bibr" rid="CR24">24</xref>]. ApoCIII is a small glycoprotein synthesized in the liver and intestine that resides predominantly on the surface of ApoB-containing lipoproteins and HDL. ApoCIII inhibits lipoprotein lipase activity and interferes with the receptor-mediated uptake of TG-rich lipoproteins, therefore delaying the clearance of TG-rich lipoproteins [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. On the other hand, a long-term increase in NEFA levels has been associated with ROS accumulation, which causes mitochondrial stress and leads to &#x003b2;-cell apoptosis [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In a catch-up growth rat model by re-feeding with high-fat diet, liraglutide prevented the increase of plasma NEFA, increased insulin secretion, increased islet pancreatic duodenal homeobox-1 (Pdx-1) and B cell lymphoma-2 (Bcl-2) expression, and reduced procaspase-3 transcription and Caspase-3 p11 subunit protein expression, which suggested that liraglutide treatment could antagonize &#x003b2;-cell apoptosis caused by elevated NEFA [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par58">Dyslipidaemia has been reported to affect vascular endothelial function by the inflammatory pathway [<xref ref-type="bibr" rid="CR29">29</xref>]. Raised non-esterified fatty acids impair insulin&#x02019;s effect on glucose uptake in skeletal muscle and could thus have detrimental effects on the vascular endothelium, which leads to premature cardiovascular disease [<xref ref-type="bibr" rid="CR30">30</xref>]. As reported previously, the&#x000a0;adhesion&#x000a0;molecules usually act as biomarkers, which mediate interactions between leukocytes and the vascular endothelium, shed from cell surfaces and become soluble&#x000a0;isoforms in the blood, namely, sVCAM-1 and sICAM-1 [<xref ref-type="bibr" rid="CR31">31</xref>]. Our study has shown that the levels of the vascular inflammatory marker sVCAM-1 are dramatically suppressed after liraglutide treatment compared to metformin treatment. However, we did not identify appreciable differences in the levels of sICAM-1 and PAI-1 after liraglutide therapy.</p><p id="Par59">Considerable evidence has demonstrated that sVCAM-1 plays an important role in the pathophysiological mechanisms of atherosclerosis [<xref ref-type="bibr" rid="CR32">32</xref>]. During a 10-year follow-up, a longitudinal study revealed that elevated circulating sVCAM-1 concentrations&#x000a0;in females with a history of gestational diabetes mellitus (GDM) not only represented the earliest high risk stage for developing type 2 diabetes, but also reflected the early stage of the pathway for the manifestation of future cardiometabolic disorders [<xref ref-type="bibr" rid="CR33">33</xref>]. It is widely known that atherosclerosis leads to macroangiopathy and is responsible for most deaths in patients with diabetes [<xref ref-type="bibr" rid="CR34">34</xref>]. Liraglutide was shown to significantly reduce the risk of major cardiovascular events in the large prospective LEADER trial [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. However, the precise mechanisms behind the antiatherogenic effect of liraglutide are not entirely clear, although several hypotheses have been proposed. First, it has been shown that in cultured human aortic endothelial cells (HAECs), liraglutide reduces the protein expression of VCAM-1 in response to TNF&#x003b1; and LPS stimulation and increases intracellular calcium and cAMP levels, leading to the phosphorylation of AMPK, which is an evolutionarily conserved fuel and stress-sensing enzyme that can be activated by calmodulin dependent protein kinase kinase-b (CAMKKb), and then downregulates monocyte adhesion, which presumably inhibits atherogenesis [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Second, in a cellular model of human umbilical vein endothelial cells (HUVECs) obtained from umbilical cords of women affected by GDM, liraglutide exposure significantly mitigated TNF&#x003b1; induced endothelial monocyte adhesion as well as VCAM-1 and ICAM-1 expression, reduced the phosphorylation of the MAPK42/44 signalling pathway, inhibited NF-kB p65 nuclear translocation, and decreased peroxynitrite levels and endothelial microvesicle (EMV) release [<xref ref-type="bibr" rid="CR40">40</xref>]. Third, after 8-week metformin treatment, TC and LDL-C were remarkably lower compared to baseline, but no significant differences were found between 120 min values and fasting values in &#x00394;TC and &#x00394;LDL-C. Moreover, no significant differences were found in plasma TC and LDL-C after liraglutide treatment. We presumed that liraglutide exert antiatherogenic mechanism, which might be not related to a decrease of LDL-C levels but might be related to an enhancement of HDL anti-inflammatory capacity [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par60">We carried out a Spearman rank correlation assay and the data showed that the reduction of 120&#x000a0;min NEFA (&#x00394;NEFA) was positively correlated with the decrease of sVCAM-1 (&#x00394;sVCAM-1) after 8-week liraglutide treatment. Our results suggest that liraglutide has beneficial effects on suppressing plasma NEFA as well as sVCAM-1 levels, which is likely to indicate that liraglutide could protect the endothelia by inhibiting monocyte cell adhesion and sVCAM-1 activation and reducing lipocyte oxidative stress and free fatty acid production, revealing an antiatherogenic effects [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par61">The strengths of this study include the randomized, parallel, active comparator design and the similarities between the liraglutide and metformin groups at baseline. To the best of our knowledge, this is the first study to verify that liraglutide treatment is more effective than metformin treatment for recent-onset type 2 diabetes mellitus in reducing NEFA after glucose intake and suppressing sVCAM-1 levels at the same time. However, this study has certain limitations. First, it has a non-blinded design, lacks a non-treatment control group, and has a small sample size for the study. Second, further studies are needed to reveal the relevant signalling pathways by which liraglutide might influence glucose and lipid metabolism, regulate vascular endothelial function, and antagonize atherosclerosis.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par62">In brief, this study demonstrated that liraglutide administration is more effective in diminishing 120 min NEFAs and suppressing sVCAM-1 levels than metformin in young patients with recent-onset type 2 diabetes mellitus. This outcome could be associated with potentiating insulin secretion capacity and antagonizing vascular inflammatory cytokines. Therefore, these results suggest that liraglutide may exert a protective effect on alleviating vascular damage, antagonizing atherosclerosis, and reducing the risk of cardiovascular disease in the course of type 2 diabetes.</p></sec><sec sec-type="supplementary-material"><title>Additional file</title><sec id="Sec15"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12933_2018_701_MOESM1_ESM.zip"><caption><p><bold>Additional file 1: Table S1.</bold> Changes of plasma lipids and lipoprotein metabolism parameters before and after 8-week treatment with liraglutide and metfotmin. <bold>Table S2.</bold> Comparisons of body weight, plasma glucose and insulin secretion capacity before and after 8-week treatment between two groups. <bold>Table S3.</bold> Comparisons of sVCAM-1,sICAM-1,PAI-1 levels before and after 8-week treatment between two groups. <bold>Table S4.</bold> Spearman rank correlations in &#x00394;NEFA with &#x00394;sVCAM-1, &#x00394;AUCins and &#x00394;I30/&#x00394;G30 after 8-week treatment.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BMI</term><def><p id="Par5">body mass index</p></def></def-item><def-item><term>WC</term><def><p id="Par6">waist circumference</p></def></def-item><def-item><term>TC</term><def><p id="Par7">total cholesterol</p></def></def-item><def-item><term>TG</term><def><p id="Par8">triglycerides</p></def></def-item><def-item><term>HDL-C</term><def><p id="Par9">high-density lipoprotein cholesterol</p></def></def-item><def-item><term>LDL-C</term><def><p id="Par10">low-density lipoprotein cholesterol</p></def></def-item><def-item><term>Apo</term><def><p id="Par11">apolipoprotein</p></def></def-item><def-item><term>FPG</term><def><p id="Par12">fasting plasma glucose</p></def></def-item><def-item><term>HbA<sub>1</sub>c</term><def><p id="Par13">glycated haemoglobin</p></def></def-item><def-item><term>SBP</term><def><p id="Par14">systolic blood pressure</p></def></def-item><def-item><term>DBP</term><def><p id="Par15">diastolic blood pressure</p></def></def-item><def-item><term>OGTT</term><def><p id="Par16">oral glucose tolerance test</p></def></def-item><def-item><term>GLP-1</term><def><p id="Par17">glucagon-like peptide-1</p></def></def-item><def-item><term>LRG</term><def><p id="Par18">liraglutide</p></def></def-item><def-item><term>MET</term><def><p id="Par19">metformin</p></def></def-item><def-item><term>NEFA</term><def><p id="Par20">non-esterified fatty acids</p></def></def-item><def-item><term>sVCAM-1</term><def><p id="Par21">soluble vascular cell adhesion molecule-1</p></def></def-item><def-item><term>sICAM-1</term><def><p id="Par22">soluble intercellular adhesion molecule-1</p></def></def-item><def-item><term>PAI-1</term><def><p id="Par23">plasminogen activator inhibitors-1</p></def></def-item><def-item><term>ELISA</term><def><p id="Par24">enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>HPLC</term><def><p id="Par25">high performance liquid chromatography</p></def></def-item><def-item><term>ECLI</term><def><p id="Par26">electrochemiluminescence immunoassay</p></def></def-item><def-item><term>CV</term><def><p id="Par27">coefficients of variation</p></def></def-item><def-item><term>ROS</term><def><p id="Par29">reactive oxygen species</p></def></def-item><def-item><term>GDM</term><def><p id="Par30">gestational diabetes mellitus</p></def></def-item><def-item><term>HAECs</term><def><p id="Par31">human aortic endothelial cells</p></def></def-item><def-item><term>AMP</term><def><p id="Par32">activated protein kinase</p></def></def-item><def-item><term>AMPK</term><def><p id="Par33">adenosine monophosphate activated protein kinase</p></def></def-item><def-item><term>CAMKKb</term><def><p id="Par34">calmodulin dependent protein kinase kinase-b</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par35">tumor necrosis factor-&#x003b1;</p></def></def-item><def-item><term>LPS</term><def><p id="Par36">lipopolysaccharide</p></def></def-item><def-item><term>HUVEC</term><def><p id="Par37">human umbilical vein endothelial cells</p></def></def-item><def-item><term>MAPK</term><def><p id="Par38">mitogen-activated protein kinase</p></def></def-item><def-item><term>NF-kB</term><def><p id="Par39">nuclear factor kappa-light-chain-enhancer of activated B cells</p></def></def-item><def-item><term>EMV</term><def><p id="Par40">endothelial microvesicle</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12933-018-0701-4) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Authors&#x02019; contributions.</title><p>XC conceived and designed the research. XC, LW, WZ, YT, CC and CQ performed the experiments. XC and WZ analysed the data. XC drafted the manuscript. All authors contributed to the writing of the manuscript. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par63">We thank all the research subjects for their participation and acknowledge the skillful work of the entire medical staff at the Department of Endocrinology and Metabolism, Zhongshan Hospital Xiamen University. We are very grateful to Shaojie Wang (Nanolab Technologies, Milpitas, California, USA) for the language polishing, Yin-xiang Huang (Xiamen Diabetes Hospital, Xiamen, P. R. China) for the NEFA measurement, Yu-bing Yan (Zhongshan Hospital Xiamen University, Xiamen, P. R. China) for the statistical analysis.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par64">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par65">All data generated or analysed during this study are included in this published article and its additional files.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par66">Not applicable.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par67">Ethical approval was granted by the Institutional Review Board of Xiamen University Zhongshan Hospital according to Helsinki Declaration II. All subjects provided written informed consent to participate.</p></sec><sec id="FPar6"><title>Funding</title><p id="Par68">This work was financially supported by the Science and Technology Benefit Fund of Xiamen Technology Bureau (3502Z20154027).</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par69">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>IM</given-names></name><name><surname>Adler</surname><given-names>AI</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Manley</surname><given-names>SE</given-names></name><name><surname>Cull</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1136/bmj.321.7258.405</pub-id><pub-id pub-id-type="pmid">10938048</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Vaccaro</surname><given-names>O</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name></person-group><article-title>Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial</article-title><source>Diabetes Care</source><year>1993</year><volume>16</volume><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.2337/diacare.16.2.434</pub-id><pub-id pub-id-type="pmid">8432214</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Knotts</surname><given-names>TA</given-names></name><name><surname>Chavez</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>LP</given-names></name><name><surname>Hoehn</surname><given-names>KL</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name></person-group><article-title>Lipid mediators of insulin resistance</article-title><source>Nutr Rev</source><year>2007</year><volume>65</volume><fpage>S39</fpage><lpage>S46</lpage><pub-id pub-id-type="doi">10.1301/nr.2007.jun.S39-S46</pub-id><pub-id pub-id-type="pmid">17605313</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>VT</given-names></name><name><surname>Petersen</surname><given-names>KF</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Lipid-induced insulin resistance: unravelling the mechanism</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>2267</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60408-4</pub-id><pub-id pub-id-type="pmid">20609972</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name></person-group><article-title>Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver</article-title><source>Curr Diab Rep.</source><year>2006</year><volume>6</volume><fpage>177</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1007/s11892-006-0031-x</pub-id><pub-id pub-id-type="pmid">16898568</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilding</surname><given-names>JP</given-names></name></person-group><article-title>The importance of free fatty acids in the development of type 2 diabetes</article-title><source>Diabet Med</source><year>2007</year><volume>24</volume><fpage>934</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2007.02186.x</pub-id><pub-id pub-id-type="pmid">17725706</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Edelstein</surname><given-names>D</given-names></name><name><surname>Obici</surname><given-names>S</given-names></name><name><surname>Higham</surname><given-names>N</given-names></name><name><surname>Zou</surname><given-names>MH</given-names></name><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group><article-title>Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation</article-title><source>J Clin Invest.</source><year>2006</year><volume>116</volume><issue>4</issue><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1172/JCI23354</pub-id><pub-id pub-id-type="pmid">16528409</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>HG</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>YY</given-names></name><name><surname>Tao</surname><given-names>YH</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Glutathione prevents free fatty acids-induced oxidative stress and apoptosis in human brain vascular endothelial cells through Akt pathway</article-title><source>CNS Neurosci Ther</source><year>2013</year><volume>19</volume><issue>4</issue><fpage>252</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1111/cns.12068</pub-id><pub-id pub-id-type="pmid">23521913</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trujillo</surname><given-names>JM</given-names></name><name><surname>Nuffer</surname><given-names>W</given-names></name></person-group><article-title>GLP-1 receptor agonists for type 2&#x000a0;diabetes&#x000a0;mellitus: recent developments and emerging agents</article-title><source>Pharmacotherapy.</source><year>2014</year><volume>34</volume><issue>11</issue><fpage>1174</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1002/phar.1507</pub-id><pub-id pub-id-type="pmid">25382096</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Retnakaran</surname><given-names>R</given-names></name><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Swaminathan</surname><given-names>B</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name></person-group><article-title>Liraglutide and the preservation of pancreatic &#x003b2;-cell function in early type 2 diabetes: the LIBRA trial</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><issue>12</issue><fpage>3270</fpage><lpage>3278</lpage><pub-id pub-id-type="doi">10.2337/dc14-0893</pub-id><pub-id pub-id-type="pmid">25249651</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>HQ</given-names></name><name><surname>Deng</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>QH</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name></person-group><article-title>Liraglutide prevents fast weight gain and &#x003b2;-cell dysfunction in male catch-up growth rats</article-title><source>Exp Biol Med (Maywood).</source><year>2015</year><volume>240</volume><issue>9</issue><fpage>1165</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1177/1535370214567614</pub-id><pub-id pub-id-type="pmid">25710926</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masmiquel</surname><given-names>L</given-names></name><name><surname>Leiter</surname><given-names>LA</given-names></name><name><surname>Vidal</surname><given-names>J</given-names></name><name><surname>Bain</surname><given-names>S</given-names></name><name><surname>Petrie</surname><given-names>J</given-names></name><name><surname>Franek</surname><given-names>E</given-names></name><etal/></person-group><article-title>LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial</article-title><source>Cardiovasc Diabetol.</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0341-5</pub-id><pub-id pub-id-type="pmid">26864124</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anagnostis</surname><given-names>P</given-names></name><name><surname>Athyros</surname><given-names>VG</given-names></name><name><surname>Adamidou</surname><given-names>F</given-names></name><name><surname>Panagiotou</surname><given-names>A</given-names></name><name><surname>Kita</surname><given-names>M</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name></person-group><article-title>Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><issue>4</issue><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01345.x</pub-id><pub-id pub-id-type="pmid">21205117</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruen</surname><given-names>R</given-names></name><name><surname>Curley</surname><given-names>S</given-names></name><name><surname>Kajani</surname><given-names>S</given-names></name><name><surname>Crean</surname><given-names>D</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>ME</given-names></name><name><surname>Lucitt</surname><given-names>MB</given-names></name><name><surname>Godson</surname><given-names>CG</given-names></name><name><surname>McGillicuddy</surname><given-names>FC</given-names></name><name><surname>Belton</surname><given-names>O</given-names></name></person-group><article-title>Liraglutide&#x000a0;dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis</article-title><source>Cardiovasc Diabetol.</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0626-3</pub-id><pub-id pub-id-type="pmid">29110715</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Glucagon-like peptide-1 receptor agonist&#x000a0;liraglutide&#x000a0;inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation</article-title><source>Cardiovasc Drugs Ther</source><year>2014</year><volume>28</volume><issue>5</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1007/s10557-014-6539-4</pub-id><pub-id pub-id-type="pmid">25022544</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiramatsu</surname><given-names>T</given-names></name><name><surname>Ozeki</surname><given-names>A</given-names></name><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Furuta</surname><given-names>S</given-names></name></person-group><article-title>Long term effects of&#x000a0;liraglutide&#x000a0;in japanese patients with type 2 diabetes among the subgroups with different renal functions: results of 2-year prospective study</article-title><source>Drug Res (Stuttg).</source><year>2017</year><volume>67</volume><issue>11</issue><fpage>640</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1055/s-0043-110603</pub-id><pub-id pub-id-type="pmid">28738426</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spadaro</surname><given-names>L</given-names></name><name><surname>Alagona</surname><given-names>C</given-names></name><name><surname>Palermo</surname><given-names>F</given-names></name><name><surname>Piro</surname><given-names>S</given-names></name><name><surname>Calanna</surname><given-names>S</given-names></name><name><surname>Parrinello</surname><given-names>G</given-names></name><name><surname>Purrello</surname><given-names>F</given-names></name><name><surname>Rabuazzo</surname><given-names>AM</given-names></name></person-group><article-title>Early phase insulin secretion is increased in subjects with normal fasting glucose and metabolic syndrome: a premature feature of beta-cell dysfunction</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2011</year><volume>21</volume><issue>3</issue><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2009.09.003</pub-id><pub-id pub-id-type="pmid">20096546</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>DB</given-names></name><name><surname>Paultre</surname><given-names>F</given-names></name><name><surname>Maggio</surname><given-names>C</given-names></name><name><surname>Mezzitis</surname><given-names>N</given-names></name><name><surname>Pi-Sunyer</surname><given-names>X</given-names></name></person-group><article-title>The use of areas under curves in diabetes research</article-title><source>Diabetes Care</source><year>1995</year><volume>18</volume><issue>2</issue><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.2337/diacare.18.2.245</pub-id><pub-id pub-id-type="pmid">7729306</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loirdighi</surname><given-names>N</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name><name><surname>Levy</surname><given-names>E</given-names></name></person-group><article-title>Insulin decreases chylomicron production in human fetal small intestine</article-title><source>Biochim Biophys Acta</source><year>1992</year><volume>1175</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/0167-4889(92)90015-4</pub-id><pub-id pub-id-type="pmid">1482690</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name><name><surname>Gethmann</surname><given-names>A</given-names></name><name><surname>Gotze</surname><given-names>O</given-names></name><name><surname>Gallwitz</surname><given-names>B</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Schmidt</surname><given-names>WE</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nonesterified fatty acids in humans</article-title><source>Diabetologia.</source><year>2006</year><volume>49</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1007/s00125-005-0126-y</pub-id><pub-id pub-id-type="pmid">16447057</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlic</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Szeto</surname><given-names>L</given-names></name><name><surname>Patterson</surname><given-names>BW</given-names></name><name><surname>Lewis</surname><given-names>GF</given-names></name></person-group><article-title>Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>580</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.2337/db09-1297</pub-id><pub-id pub-id-type="pmid">20028946</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>J</given-names></name><name><surname>Longuet</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>CL</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Federico</surname><given-names>LM</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Adeli</surname><given-names>K</given-names></name></person-group><article-title>The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1611-5</pub-id><pub-id pub-id-type="pmid">19957161</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cianflone</surname><given-names>K</given-names></name><name><surname>Paglialunga</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>C</given-names></name></person-group><article-title>Intestinally derived lipids: metabolic regulation and consequences&#x02013;an overview</article-title><source>Atheroscler Suppl.</source><year>2008</year><volume>9</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosissup.2008.05.014</pub-id><pub-id pub-id-type="pmid">18693144</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>EA</given-names></name><name><surname>Koska</surname><given-names>J</given-names></name><name><surname>Mullin</surname><given-names>MP</given-names></name><name><surname>Syoufi</surname><given-names>I</given-names></name><name><surname>Schwenke</surname><given-names>DC</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name></person-group><article-title>Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset of type 2 diabetes mellitus</article-title><source>Atherosclerosis.</source><year>2010</year><volume>212</volume><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.05.028</pub-id><pub-id pub-id-type="pmid">20557887</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CS</given-names></name><name><surname>McConathy</surname><given-names>WJ</given-names></name><name><surname>Kloer</surname><given-names>HU</given-names></name><name><surname>Alaupovic</surname><given-names>P</given-names></name></person-group><article-title>Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III</article-title><source>J Clin Invest.</source><year>1985</year><volume>75</volume><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1172/JCI111711</pub-id><pub-id pub-id-type="pmid">3973011</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavey</surname><given-names>V</given-names></name><name><surname>Lestavel-Delattre</surname><given-names>S</given-names></name><name><surname>Copin</surname><given-names>C</given-names></name><name><surname>Bard</surname><given-names>JM</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name></person-group><article-title>Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1995</year><volume>15</volume><fpage>963</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.15.7.963</pub-id><pub-id pub-id-type="pmid">7600129</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaney</surname><given-names>GC</given-names></name><name><surname>Corkey</surname><given-names>BE</given-names></name></person-group><article-title>Fatty acid metabolism and insulin secretion in pancreatic beta cells</article-title><source>Diabetologia</source><year>2003</year><volume>46</volume><fpage>1297</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1007/s00125-003-1207-4</pub-id><pub-id pub-id-type="pmid">13680127</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newsholme</surname><given-names>P</given-names></name><name><surname>Haber</surname><given-names>EP</given-names></name><name><surname>Hirabara</surname><given-names>SM</given-names></name><name><surname>Rebelato</surname><given-names>ELO</given-names></name><name><surname>Procopio</surname><given-names>J</given-names></name><name><surname>Morgan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Diabetes associated cell stress and dysfunction: role of mitochondrial and nonmitochondrial ROS production and activity</article-title><source>J Physiol</source><year>2007</year><volume>583</volume><issue>1</issue><fpage>9</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2007.135871</pub-id><pub-id pub-id-type="pmid">17584843</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>KT</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Kanthimathi</surname><given-names>MS</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Nesaretnam</surname><given-names>K</given-names></name></person-group><article-title>Effects of amount and type of dietary fats on postprandial lipemia and thrombogenic markers in individuals with metabolic syndrome</article-title><source>Atherosclerosis.</source><year>2015</year><volume>242</volume><issue>1</issue><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.07.003</pub-id><pub-id pub-id-type="pmid">26232169</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>HO</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name></person-group><article-title>Vascular function, insulin resistance and fatty acids</article-title><source>Diabetologia</source><year>2002</year><volume>45</volume><issue>5</issue><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1007/s00125-002-0800-2</pub-id><pub-id pub-id-type="pmid">12107742</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zonneveld</surname><given-names>R</given-names></name><name><surname>Martinelli</surname><given-names>R</given-names></name><name><surname>Shapiro</surname><given-names>NI</given-names></name><name><surname>Kuijpers</surname><given-names>TW</given-names></name><name><surname>Plotz</surname><given-names>FB</given-names></name><name><surname>Carman</surname><given-names>CV</given-names></name></person-group><article-title>Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults</article-title><source>Crit Care</source><year>2014</year><volume>18</volume><fpage>204</fpage><pub-id pub-id-type="doi">10.1186/cc13733</pub-id><pub-id pub-id-type="pmid">24602331</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eupen</surname><given-names>MG</given-names></name><name><surname>Schram</surname><given-names>MT</given-names></name><name><surname>Colhoun</surname><given-names>HM</given-names></name><name><surname>Hanssen</surname><given-names>NM</given-names></name><name><surname>Niessen</surname><given-names>HW</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><etal/></person-group><article-title>The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1</article-title><source>Diabetologia</source><year>2013</year><volume>56</volume><issue>8</issue><fpage>1845</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1007/s00125-013-2919-8</pub-id><pub-id pub-id-type="pmid">23620061</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;bl</surname><given-names>CS</given-names></name><name><surname>Bozkurt</surname><given-names>L</given-names></name><name><surname>Yarragudi</surname><given-names>R</given-names></name><name><surname>Prikoszovich</surname><given-names>T</given-names></name><name><surname>Tura</surname><given-names>A</given-names></name><name><surname>Pacini</surname><given-names>G</given-names></name><name><surname>Koppensteiner</surname><given-names>R</given-names></name><name><surname>Kautzky-Willer</surname><given-names>A</given-names></name></person-group><article-title>A Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus</article-title><source>Cardiovasc Diabetol.</source><year>2014</year><volume>13</volume><fpage>138</fpage><pub-id pub-id-type="doi">10.1186/s12933-014-0138-3</pub-id><pub-id pub-id-type="pmid">25281032</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>JA</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title><source>JAMA</source><year>2002</year><volume>287</volume><issue>19</issue><fpage>2570</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1001/jama.287.19.2570</pub-id><pub-id pub-id-type="pmid">12020339</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>M</given-names></name><name><surname>Rizvi</surname><given-names>AA</given-names></name><name><surname>Patti</surname><given-names>AM</given-names></name><name><surname>Nikolic</surname><given-names>D</given-names></name><name><surname>Giglio</surname><given-names>RV</given-names></name><name><surname>Castellino</surname><given-names>G</given-names></name><etal/></person-group><article-title>Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study</article-title><source>Cardiovasc Diabetol.</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>162</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0480-8</pub-id><pub-id pub-id-type="pmid">27912784</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marso</surname><given-names>SP</given-names></name><name><surname>Daniels</surname><given-names>GH</given-names></name><name><surname>Brown-Frandsen</surname><given-names>K</given-names></name><name><surname>Kristensen</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><etal/></person-group><article-title>liraglutide and cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med.</source><year>2016</year><volume>375</volume><issue>4</issue><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1603827</pub-id><pub-id pub-id-type="pmid">27295427</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verg&#x000e8;s</surname><given-names>B</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name></person-group><article-title>After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?</article-title><source>Diabetes Metab.</source><year>2017</year><volume>43</volume><issue>Suppl 1</issue><fpage>S3</fpage><lpage>12</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawley</surname><given-names>S</given-names></name><name><surname>Selbert</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>E</given-names></name><name><surname>Edelman</surname><given-names>A</given-names></name><name><surname>Carling</surname><given-names>D</given-names></name><etal/></person-group><article-title>5&#x02032;-AMP activates the AMP-activated protein kinase cascade, and Ca2&#x02009;+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>27186</fpage><lpage>27191</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.45.27186</pub-id><pub-id pub-id-type="pmid">7592975</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasner</surname><given-names>NM</given-names></name><name><surname>Ido</surname><given-names>Y</given-names></name><name><surname>Ruderman</surname><given-names>NB</given-names></name><name><surname>Cacicedo</surname><given-names>JM</given-names></name></person-group><article-title>Glucagon-like peptide-1(GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>5</issue><fpage>e9755</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0097554</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Tomo</surname><given-names>P</given-names></name><name><surname>Lanuti</surname><given-names>P</given-names></name><name><surname>Di Pietro</surname><given-names>N</given-names></name><name><surname>Baldassarre</surname><given-names>MPA</given-names></name><name><surname>Marchisio</surname><given-names>M</given-names></name><name><surname>Pandolfi</surname><given-names>A</given-names></name><name><surname>Consoli</surname><given-names>A</given-names></name><name><surname>Formoso</surname><given-names>G</given-names></name></person-group><article-title>Liraglutide mitigates TNF-&#x003b1; induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women</article-title><source>Diabetes Metab Res Rev.</source><year>2017</year><volume>33</volume><fpage>e2925</fpage><pub-id pub-id-type="doi">10.1002/dmrr.2925</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebtehaj</surname><given-names>S</given-names></name><name><surname>Gruppen</surname><given-names>EG</given-names></name><name><surname>Parvizi</surname><given-names>M</given-names></name><name><surname>Tietge</surname><given-names>UJF</given-names></name><name><surname>Dullaart</surname><given-names>RPF</given-names></name></person-group><article-title>The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation</article-title><source>Cardiovasc Diabetol.</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>132</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0613-8</pub-id><pub-id pub-id-type="pmid">29025405</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nystrom</surname><given-names>T</given-names></name><name><surname>Gutniak</surname><given-names>MK</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease</article-title><source>Am J Physiol Endocrinol Metab.</source><year>2004</year><volume>287</volume><issue>6</issue><fpage>E1209</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00237.2004</pub-id><pub-id pub-id-type="pmid">15353407</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>PC</given-names></name><name><surname>Liu</surname><given-names>LF</given-names></name><name><surname>Jou</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>HK</given-names></name></person-group><article-title>The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and&#x000a0;micturition deficits induced by middle cerebral artery occlusion in diabetic mice</article-title><source>BMC Neurosci.</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s12868-016-0272-9</pub-id><pub-id pub-id-type="pmid">27296974</pub-id></element-citation></ref></ref-list></back></article>